Østergaard, M, Van Vollenhoven, R, Rudin, A, Hetland, M L, Heiberg, M, Nordström, D, Nurmohamed, M, Gudbjornsson, B, Ørnbjerg, L M, Bøyesen, P, Olsen, I, Lend, K, Hørslev-Petersen, K, Uhlig, T, Sokka-Isler, T, Gröndal, G, Krabbe, S, Lindqvist, J, Gjertsson, I, Glinatsi, D, Kapetanovic, M C, Aga, A B, Faustini, F, Parmanne, P, Lorenzen, T, Cagnotto, G, Back, J, Hendricks, O, Vedder, D, Rannio, T, Grenholm, E, Lindegaard, H M, Ljosa, M K A, Brodin, E, Soderbergh, A, Rizk, M, Hermansson, E, Uhrenholt, L, Larsson, P, Just, S A, Bakland, G, Stevens, D, Laurberg, T B, Haavardsholm, E A, Lampa, J & NORD-STAR Study Group 2022, ' CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONALTHERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STARTRIAL ', Annals of the Rheumatic Diseases, vol. 81, no. Suppl. 1, OP0058, pp. 38-40 . https://doi.org/10.1136/annrheumdis-2022-eular.868